(19)
(11) EP 1 835 929 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.07.2016 Bulletin 2016/30

(45) Mention of the grant of the patent:
04.05.2016 Bulletin 2016/18

(21) Application number: 06700713.8

(22) Date of filing: 06.01.2006
(51) International Patent Classification (IPC): 
A61K 38/20(2006.01)
A61K 39/395(2006.01)
C07K 16/28(2006.01)
 A61K 39/00(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/EP2006/050072
(87) International publication number:
WO 2006/072625 (13.07.2006 Gazette 2006/28)

(54)

ANTI-KIR COMBINATION TREATMENTS AND METHODS

BEHANDLUNGEN UND VERFAHREN MIT ANTI-KIR-KOMBINATION

PROCÉDÉS ET TRAITEMENTS COMBINÉS ANTI-KIR

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 06.01.2005 DK 200500026

(43) Date of publication of application:
26.09.2007 Bulletin 2007/39

(60) Divisional application:
11181366.3 / 2446897
16167879.2

(73) Proprietors:
  • NOVO NORDISK A/S
    2880 Bagsvaerd (DK)
  • Innate Pharma S.A.
    13009 Marseille (FR)

(72) Inventors:
  • ROMAGNÉ , Francois
    F-13600 La Ciotat (FR)
  • WAGTMANN, Peter Andreas Nicolai Reumert
    DK-2960 Rungsted Kyst (DK)
  • GLAMANN, Joakim
    DK-2820 Gentofte (DK)

(74) Representative: Reitstötter Kinzebach 
Patentanwälte Sternwartstrasse 4
81679 München
81679 München (DE)


(56) References cited: : 
WO-A1-2005/009465
 WO-A2-2005/003172
   
  • KOH CRYSTAL Y ET AL: "Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo" BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 97, no. 10, 15 May 2001 (2001-05-15), pages 3132-3137, XP002308582 ISSN: 0006-4971 cited in the application
  • KOH C Y ET AL: "NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution" BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US, vol. 8, no. 1, 2002, pages 17-25, XP002308879 ISSN: 1083-8791
  • KOGURE T ET AL: "Killer-cell inhibitory receptors, CD158a/b, are upregulated by interleukin-2, but not interferon-gamma or interleukin-4." MEDIATORS OF INFLAMMATION. 1999, vol. 8, no. 6, 1999, pages 313-318, XP008066290 ISSN: 0962-9351
  • SONDEL P M ET AL: "COMBINATION THERAPY WITH INTERLEUKIN-2 AND ANTITUMOR MONOCLONAL ANTIBODIES" CANCER JOURNAL FROM SCIENTIFIC AMERICAN, SCIENTIFIC AMERICAN, INC., NEW YORK, NY, US, vol. 3, no. SUPPL 1, 1997, pages S121-S127, XP009040777 ISSN: 1081-4442
  • FARAG SHERIF S ET AL: "New directions in natural killer cell-based immunotherapy of human cancer." EXPERT OPINION ON BIOLOGICAL THERAPY. APR 2003, vol. 3, no. 2, April 2003 (2003-04), pages 237-250, XP009040774 ISSN: 1471-2598
  • MORETTA A ET AL.: "P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities", J.EXP.MED., vol. 178, August 1993 (1993-08), pages 597-604, XP009005922,
  • CAMBIAGGI A. ET AL.: "Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor.", PROC. NATL. ACAD. SCI. USA, vol. 94, July 1997 (1997-07), pages 8088-8092, XP002007252,
  • RUGGERI L ET AL.: "Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants", SCIENCE, vol. 295, 15 March 2002 (2002-03-15), pages 2097-2100, XP002382437,
  • VIVIER E AND ANFOSSI N: "Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future", NATURE REVIEWS IMMUNOLOGY, vol. 4, March 2004 (2004-03), pages 190-198, XP008066093,
  • ABI-RACHED L AND PARHAM P: "Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues", J.EXP.MED., vol. 201, no. 8, 18 May 2005 (2005-05-18), pages 1319-1332,
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).